SUMMARY Cerebrospinal fluid levels of homovanillic acid (HVA) 
Studies of necropsy brain tissue and cerebrospinal fluid have demonstrated a relationship between the motor deficit in Parkinson's disease and levels of dopamine (DA) and homovanillic acid (HVA). '-8 In contrast CSF levels of 5-hydroxyindolacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) have not been found to be altered in Par- kinson's disease.47-8 However, levels of brain noreprinephrine (NE) and MHPG are reported as low in certain brain regions postmortem. 9 Other neurochemical findings reported in Parkinson's disease include: decreased activity of dopa decarboxylase in the striatum,'0 alterations in striatal neuroleptic binding" and cortical serotonin binding;'2 and reduced methionine-enkephalin levels in the substantia nigra and the ventral tegmental area. '3 In contrast to the detailed studies of the relationship between the dopaminergic system and the motor deficit, there are no published studies examining the relationship between central catecholamine metabolism and the cognitive deficit in Parkinson's disease. Yet there are reports that levodopa therapy can improve both cognitive function and motor function in Parkinson's disease.'4'-6 A positive correlation has also been reported between the degree of dementia and bradykinesia'7 which in turn has been reported elsewhere to correlate with the deficit in CSF and brain HVA levels. Furthermore there is evidence suggesting it is actually the relative balance of dopaminergic and noradrenergic activity that is important for optimal cognitive function.'8 We therefore thought it of interest to examine the potential relationship of motor and cognitive performance in Parkinson's disease with CSF levels of both HVA and MHPG (the major metabolite of norepinephrine in the CNS) and platelet monoamine oxidase activity (a peripheral source of MAO B, the major intraneuronal degradative enzyme for DA in human striatum). '9 Method and subjects (3) attention (digit span). Levels of HVA and MHPG were measured in CSF collected by lumbar puncture performed at 0900 hours in inpatients after 24 hours on a low amine diet (adapted from that prescribed for patients on monoamine oxidase inhibitors). The first 15 ml of CSF was discarded and the next 8 ml used for the catecholamine assays. Platelet MAO samples were taken within 24 hours of the lumbar puncture. HVA and MHPG were measured using a gas chromatographic technique with electron capture.242S Platelet MAO enzyme kinetics were measured using '4C-phenyethylamine and enzyme activity using '4C-tyramine according to our previously published methods.26 All assays were done in duplicate on coded samples by technicians blind to the clinical data. Results were compared to a group of age-matched drug-free normal male controls who had platelet MAO measured and a second group of male inpatient controls who were being investigated for low back pain and headache, where no neurological cause was found and in whom CSF was collected and MHPG and HVA measured in the same manner as for the Parkinsonion group.
Results
The 17 Parkinson patients studied had a duration of illness of 13 We also found no differences in platelet MAO enzyme kinetics between the diseased and the control groups which is consistent with the one published study of platelet MAO activity in Parkinson's The pattern of correlation after controlling for age between the cognitive test subscores on the Guild Memory Scale and the levels of HVA and MHPG in the CSF was intriguing. We found a statistically significant negative correlation between CSF MHPG and scores on the digit span and a trend for a similar finding (p < 0-10) with the paragraphs and paired associates subscales. Norepinephrine has been shown in animal studies35 to act as a neuromodulator in facilitating memory functions and our findings in Parkinson's disease suggest a role in cognitive function for NE in man.
We could not rule out an effect for DA in cognitive function in Parkinson's disease because platelet MAO activity and HVA levels showed similar relationships with cognitive deficit that reached statistical significance where higher MAO B activity was associated with higher scores on the MSQ and 5/6 Guild Memory Scale subscores. Consistent with the relationship of MAO B with cognitive function, HVA levels tended to show positive correlations with cognitive function. The ratio of HVA to MHPG correlated significantly with 3/6 Guild subscales and similarly the combination of the two independent variables, platelet MAO V.. and MHPG contributed significantly to the variance on 4/6 subscales. While these findings suggest a relationship between NE and/or DA and cognitive function, an alternative suggestion is that an imbalance created by DA underfunction and relatively normal NE activity may contribute to the abnormality in cognitive functioning in Parkinson's disease.'8 Clearly a larger series of patients must be studied to see if these data can be confirmed and to investigate these suggested causal relationships.
Our findings suggest that while the motor deficit of Parkinson's disease is related to a deficiency of dopamine in nigrostriatal neurons, certain aspects of cognitive function or dysfunction appear related to both NE and DA or perhaps the relative imbalance that develops between the dopaminergic system and noradrenergic function. These observations emphasise the need for further study of the functional interrelationship between these aminergic systems and cognitive and motor function in order to permit a
